Genetic determinants of on-aspirin platelet reactivity: Focus on the influence of PEAR1

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Würtz, Morten ^a,b   Nissen, Peter H ^a   Grove, Erik Lerkevang ^a   Kristensen, Steen Dalby ^a   Hvas, Anne Mette ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b REGIONAL HOSPITAL WEST JUTLAND   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; PADGEM PROTEIN; CELL SURFACE RECEPTOR; PEAR1 PROTEIN, HUMAN; PTGS1 PROTEIN, HUMAN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; CORONARY ARTERY DISEASE; DANISH CITIZEN; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENE LOCATION; GENE PRODUCT; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MONOTHERAPY; PATIENT COMPLIANCE; PLATELET ENDOTHELIAL AGGREGATION RECEPTOR 1 GENE; PLATELET REACTIVITY; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; DRUG EFFECTS; GENETICS; GENOTYPE; METABOLISM;

AGED; ASPIRIN; CORONARY ARTERY DISEASE; CYCLOOXYGENASE 1; FEMALE; GENOTYPE; HUMANS; MALE; PLATELET AGGREGATION; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CELL SURFACE;

EID: 84909992705     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111816     Document Type: Article

References (35)

1. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative metaanalysis of individual participant data from randomised trials. Lancet 373: 1849-1860.
2. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR (2008) Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and metaanalysis. BMJ 336: 195-198.
3. Wurtz M, Grove EL (2012) Interindividual variability in the efficacy of oral antiplatelet drugs: definitions, mechanisms and clinical importance. Curr Pharm Des 18: 5344-5361.
4. Roberts R, Stewart AF (2012) Genes and Coronary Artery Disease: Where Are We? J Am Coll Cardiol 60: 1715-1721.
5. O'Donnell CJ, Larson MG, Feng D, Sutherland PA, Lindpaintner K, et al. (2001) Genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation 103: 3051-3056.
6. Faraday N, Yanek LR, Mathias R, Herrera-Galeano JE, Vaidya D, et al. (2007) Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation 115: 2490-2496.
7. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C (2005) Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353: 2373-2383.
8. Andre P, LaRocca T, Delaney SM, Lin PH, Vincent D, et al. (2003) Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis. Circulation 108: 2697-2703.
9. Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, et al. (2007) Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 115: 3156-3164.
10. Wurtz M, Lordkipanidze M, Grove EL (2013) Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor antagonists. J Thromb Haemost 11: 1627-1639.
11. Faraday N, Yanek LR, Yang XP, Mathias R, Herrera-Galeano JE, et al. (2011) Identification of a specific intronic PEAR1 gene variant associated with greater platelet aggregability and protein expression. Blood 118: 3367-3375.
12. Johnson AD, Yanek LR, Chen MH, Faraday N, Larson MG, et al. (2010) Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists. Nat Genet 42: 608-613.
13. Lewis JP, Ryan K, O'Connell JR, Horenstein RB, Damcott CM, et al. (2013) Genetic Variation in PEAR1 is Associated with Platelet Aggregation and Cardiovascular Outcomes. Circ Cardiovasc Genet 6: 184-192.
14. Nanda N, Bao M, Lin H, Clauser K, Komuves L, et al. (2005) Platelet endothelial aggregation receptor 1 (PEAR1), a novel epidermal growth factor repeat-containing transmembrane receptor, participates in platelet contactinduced activation. J Biol Chem 280: 24680-24689.
15. Kauskot A, Di MM, Loyen S, Freson K, Verhamme P, et al. (2012) A novel mechanism of sustained platelet alphaIIbbeta3 activation via PEAR1. Blood 119: 4056-4065.
16. Schmidt M, Maeng M, Jakobsen CJ, Madsen M, Thuesen L, et al. (2010) Existing data sources for clinical epidemiology: The Western Denmark Heart Registry. Clin Epidemiol 2: 137-144.
17. Grove EL, Storey RF, Wurtz M (2012) Platelet function testing in atherothrombotic disease. Curr Pharm Des 18: 5379-5391.
18. Wurtz M, Kristensen SD, Hvas AM, Grove EL (2012) Pharmacogenetics of the antiplatelet effect of aspirin. Curr Pharm Des 18: 5294-5308.
19. Lunetta KL (2008) Genetic association studies. Circulation 118: 96-101.
20. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, et al. (2001) dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 29: 308-311.
21. Armstrong PC, Dhanji AR, Tucker AT, Mitchell JA, Warner TD (2010) Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy. J Thromb Haemost 8: 613-615.
22. Schwartz KA, Schwartz DE, Barber K, Reeves M, De Franco AC (2008) Noncompliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients. J Transl Med 6: 46.
23. Kim Y, Suktitipat B, Yanek LR, Faraday N, Wilson AF, et al. (2013) Targeted deep resequencing identifies coding variants in the PEAR1 gene that play a role in platelet aggregation. PLoS One 8: e64179.
24. Kauskot A, Vandenbriele C, Louwette S, Gijsbers R, Tousseyn T, et al. (2013) PEAR1 attenuates megakaryopoiesis via control of the PI3K/PTEN pathway. Blood 121: 5208-5217.
25. Wurtz M, Grove EL, Kristensen SD, Hvas AM (2010) The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart 96: 368-371.
26. Herrera-Galeano JE, Becker DM, Wilson AF, Yanek LR, Bray P, et al. (2008) A novel variant in the platelet endothelial aggregation receptor-1 gene is associated with increased platelet aggregability. Arterioscler Thromb Vasc Biol 28: 1484-1490.
27. Goodman T, Ferro A, Sharma P (2008) Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol 66: 222-232.
28. Gurbel PA, Tantry US, Shuldiner AR, Kereiakes DJ (2010) Genotyping: one piece of the puzzle to personalize antiplatelet therapy. J Am Coll Cardiol 56: 112-116.
29. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, et al. (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 32: 2999-3054.
30. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, et al. (2012) An integrated map of genetic variation from 1,092 human genomes. Nature 491: 56-65.
31. Lordkipanidze M, Diodati JG, Palisaitis DA, Schampaert E, Turgeon J, et al. (2011) Genetic determinants of response to aspirin: Appraisal of 4 candidate genes. Thromb Res 128: 47-53.
32. Conneely KN, Boehnke M (2010) Meta-analysis of genetic association studies and adjustment for multiple testing of correlated SNPs and traits. Genet Epidemiol 34: 739-746.
33. Wurtz M, Hvas AM, Christensen KH, Rubak P, Kristensen SD, et al. (2013) Rapid evaluation of platelet function using the Multiplate(R) Analyzer. Platelets, 2013. doi:10.3109/09537104.2013.849804.
34. Frelinger AL 3rd, Michelson AD, Wiviott SD, Trenk D, Neumann FJ, et al. (2011) Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thromb Haemost 106: 219-226.
35. Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, et al. (2003) Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 108: 989-995.